A groundbreaking precision oncology trial is utilizing a functional proteomics and phosphoproteomics assay for treatment decision-making in a pan-tumor study. This trial represents a crucial advancement in personalized cancer care, as it aims to tailor treatment plans according to the unique protein expression and phosphorylation profiles of each patient's tumor. By incorporating this innovative approach, researchers hope to improve outcomes for individuals with cancer by targeting specific molecular pathways. This trial is set to enroll a significant number of participants across various types of cancer, making it a promising initiative in the field of oncology research.